08:19 AM EDT, 04/19/2024 (MT Newswires) -- Ocugen ( OCGN ) said Friday it has completed dosing in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA), a modifier gene therapy to treat age-related macular degeneration.

The company said the trial will evaluate the safety of unilateral subretinal administration of OCU410 in participants with geographic atrophy.